Jun 3, 2016 1 min read

CANONSBURG – Mylan N.V. Friday announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP.

The medicine is a generic version of Pharmacia and Upjohn’s Cleocin Solution, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.

Mylan, which has its administrative operations based in Southpointe, received final approval for the generic version from the U.S. Food and Drug Administration.

Cleocin Solution had U.S. sales of $30.9 million for the 12 months ending March 31, according to IMS Health.